143 related articles for article (PubMed ID: 37096420)
1.
Dullea JT; Chaluts D; Vasan V; Rutland JW; Gill CM; Ellis E; Kinoshita Y; McBride RB; Bederson J; Donovan M; Sebra R; Umphlett M; Shrivastava RK
Br J Neurosurg; 2023 Apr; ():1-7. PubMed ID: 37096420
[TBL] [Abstract][Full Text] [Related]
2. NF2 mutations are associated with resistance to radiation therapy for grade 2 and grade 3 recurrent meningiomas.
Vasan V; Dullea JT; Devarajan A; Ali M; Rutland JW; Gill CM; Kinoshita Y; McBride RB; Gliedman P; Bederson J; Donovan M; Sebra R; Umphlett M; Shrivastava RK
J Neurooncol; 2023 Jan; 161(2):309-316. PubMed ID: 36436149
[TBL] [Abstract][Full Text] [Related]
3. Clinical and genomic differences in supratentorial versus infratentorial NF2 mutant meningiomas.
Tabor JK; O'Brien J; Vasandani S; Vetsa S; Lei H; Jalal MI; Marianayagam NJ; Jin L; Millares Chavez M; Haynes J; Dincer A; Yalcin K; Aguilera SM; Omay SB; Mishra-Gorur K; McGuone D; Morales-Valero SF; Fulbright RK; Gunel M; Erson-Omay EZ; Moliterno J
J Neurosurg; 2023 Dec; 139(6):1648-1656. PubMed ID: 37243548
[TBL] [Abstract][Full Text] [Related]
4. First insight into the somatic mutation burden of neurofibromatosis type 2-associated grade I and grade II meningiomas: a case report comprehensive genomic study of two cranial meningiomas with vastly different clinical presentation.
Dewan R; Pemov A; Dutra AS; Pak ED; Edwards NA; Ray-Chaudhury A; Hansen NF; Chandrasekharappa SC; Mullikin JC; Asthagiri AR; ; Heiss JD; Stewart DR; Germanwala AV
BMC Cancer; 2017 Feb; 17(1):127. PubMed ID: 28193203
[TBL] [Abstract][Full Text] [Related]
5. Distinct genomic subclasses of high-grade/progressive meningiomas: NF2-associated, NF2-exclusive, and NF2-agnostic.
Williams EA; Santagata S; Wakimoto H; Shankar GM; Barker FG; Sharaf R; Reddy A; Spear P; Alexander BM; Ross JS; Brastianos PK; Cahill DP; Ramkissoon SH; Juratli TA
Acta Neuropathol Commun; 2020 Oct; 8(1):171. PubMed ID: 33087175
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of NF2 alteration in grade I meningiomas revisited; prognostic impact integrated with extent of resection, tumour location, and Ki-67 index.
Teranishi Y; Okano A; Miyawaki S; Ohara K; Ishigami D; Hongo H; Dofuku S; Takami H; Mitsui J; Ikemura M; Komura D; Katoh H; Ushiku T; Ishikawa S; Shin M; Nakatomi H; Saito N
Acta Neuropathol Commun; 2022 May; 10(1):76. PubMed ID: 35570314
[TBL] [Abstract][Full Text] [Related]
7. Comparative genomic analysis of driver mutations in matched primary and recurrent meningiomas.
Loewenstern J; Rutland J; Gill C; Arib H; Pain M; Umphlett M; Kinoshita Y; McBride R; Donovan M; Sebra R; Bederson J; Fowkes M; Shrivastava R
Oncotarget; 2019 May; 10(37):3506-3517. PubMed ID: 31191822
[TBL] [Abstract][Full Text] [Related]
8. Aggressive high-grade NF2 mutant meningiomas downregulate oncogenic YAP signaling via the upregulation of VGLL4 and FAT3/4.
Parrish AG; Arora S; Thirimanne HN; Rudoy D; Schmid S; Sievers P; Sahm F; Holland EC; Szulzewsky F
bioRxiv; 2024 May; ():. PubMed ID: 38854109
[TBL] [Abstract][Full Text] [Related]
9. Association of frequent NF2 mutations with spinal location predominance and worse outcomes in psammomatous meningiomas.
Ren L; Xie Q; Deng J; Chen J; Yu J; Wang D; Wakimoto H; Gong Y; Hua L
J Neurosurg; 2024 Mar; ():1-9. PubMed ID: 38552238
[TBL] [Abstract][Full Text] [Related]
10. ARID1A mutation associated with recurrence and shorter progression-free survival in atypical meningiomas.
Chaluts D; Dullea JT; Ali M; Vasan V; Devarajan A; Rutland JW; Gill CM; Ellis E; Kinoshita Y; McBride RB; Bederson J; Donovan M; Sebra R; Umphlett M; Shrivastava RK
J Cancer Res Clin Oncol; 2023 Jul; 149(8):5165-5172. PubMed ID: 36348021
[TBL] [Abstract][Full Text] [Related]
11.
Sakai Y; Miyawaki S; Teranishi Y; Okano A; Ohara K; Hongo H; Ishigami D; Shimada D; Mitsui J; Nakatomi H; Saito N
Cancers (Basel); 2022 Jun; 14(13):. PubMed ID: 35804955
[TBL] [Abstract][Full Text] [Related]
12. Somatic mutation landscape in a cohort of meningiomas that have undergone grade progression.
Cain SA; Pope B; Mangiola S; Mantamadiotis T; Drummond KJ
BMC Cancer; 2023 Mar; 23(1):216. PubMed ID: 36882706
[TBL] [Abstract][Full Text] [Related]
13. Specific gene expression signatures of low grade meningiomas.
Tsitsikov EN; Hameed S; Tavakol SA; Stephens TM; Tsytsykova AV; Garman L; Bi WL; Dunn IF
Front Oncol; 2023; 13():1126550. PubMed ID: 36937440
[TBL] [Abstract][Full Text] [Related]
14. Clinical and genomic factors associated with seizures in meningiomas.
Gupte TP; Li C; Jin L; Yalcin K; Youngblood MW; Miyagishima DF; Mishra-Gorur K; Zhao AY; Antonios J; Huttner A; McGuone D; Blondin NA; Contessa JN; Zhang Y; Fulbright RK; Gunel M; Erson-Omay Z; Moliterno J
J Neurosurg; 2020 Dec; 135(3):835-844. PubMed ID: 33276341
[TBL] [Abstract][Full Text] [Related]
15. Everolimus and Bevacizumab in the Management of Recurrent, Progressive Intracranial NF2 Mutated Meningioma.
Mathew Thomas V; Bindal P; Vredenburgh JJ
Case Rep Oncol; 2019; 12(1):126-130. PubMed ID: 31043950
[TBL] [Abstract][Full Text] [Related]
16. Multiple meningiomas: differential involvement of the NF2 gene in children and adults.
Evans DG; Watson C; King A; Wallace AJ; Baser ME
J Med Genet; 2005 Jan; 42(1):45-8. PubMed ID: 15635074
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic and genomic profiling of chordoid meningioma: implications for clinical management.
Daoud EV; Zhu K; Mickey B; Mohamed H; Wen M; Delorenzo M; Tran I; Serrano J; Hatanpaa KJ; Raisanen JM; Snuderl M; Cai C
Acta Neuropathol Commun; 2022 Apr; 10(1):56. PubMed ID: 35440040
[TBL] [Abstract][Full Text] [Related]
18. Landscape of genetic variants in sporadic meningiomas captured with clinical genomics.
Leclair NK; Shen E; Wu Q; Wolansky L; Becker K; Li L; Bulsara KR
Acta Neurochir (Wien); 2022 Sep; 164(9):2491-2503. PubMed ID: 35881312
[TBL] [Abstract][Full Text] [Related]
19. Molecular landscapes of longitudinal NF2/22q and non-NF2/22q meningiomas show different life histories.
Ng HK; Li KK; Chung NY; Chan JY; Poon MF; Wong QH; Kwan JS; Poon WS; Chen H; Chan DT; Shi ZF; Mao Y
Brain Pathol; 2023 May; 33(3):e13120. PubMed ID: 36167400
[TBL] [Abstract][Full Text] [Related]
20. Whole-Exome Sequencing Reveals Recurrent but Heterogeneous Mutational Profiles in Sporadic WHO Grade 1 Meningiomas.
González-Tablas M; Prieto C; Arandia D; Jara-Acevedo M; Otero Á; Pascual D; Ruíz L; Álvarez-Twose I; García-Montero AC; Orfao A; Tabernero MD
Front Oncol; 2021; 11():740782. PubMed ID: 34868937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
